REVENUES

12 Months Ended

Dec. 31, 2024

Revenue from Contract with Customer [Abstract]

REVENUES

REVENUES

Disaggregation of Revenues

The following table summarizes our Total revenues:

	Year Ended December 31, 2024								Year Ended December 31, 2023								Year Ended December 31, 2022
(in millions)	U.S.		Europe(6)		Rest of World(6)		Total		U.S.		Europe(6)		Rest of World(6)		Total		U.S.		Europe(6)		Rest of World(6)		Total
Product sales:
HIV
Biktarvy	$	10,855	$	1,509	$	1,060	$	13,423	$	9,692	$	1,253	$	905	$	11,850	$	8,510	$	1,103	$	777	$	10,390
Descovy	1,902		100		110		2,113		1,771		100		114		1,985		1,631		118		123		1,872
Genvoya	1,498		180		84		1,762		1,752		205		103		2,060		1,983		284		136		2,404
Odefsey	957		290		41		1,288		1,012		294		44		1,350		1,058		364		47		1,469
Symtuza - Revenue share(1)	450		130		12		592		382		133		13		529		348		168		14		530
Other HIV(2)	257		129		48		434		238		116		47		401		290		182		59		530
Total HIV	15,918		2,339		1,355		19,612		14,848		2,102		1,226		18,175		13,820		2,219		1,155		17,194
Liver Disease
Sofosbuvir/Velpatasvir(3)	922		299		374		1,596		859		323		355		1,537		844		355		331		1,530
Vemlidy	486		44		428		959		410		38		414		862		429		35		379		842
Other Liver Disease(4)	192		202		73		467		152		150		83		385		167		135		124		426
Total Liver Disease	1,601		545		876		3,021		1,421		511		852		2,784		1,440		525		833		2,798
Veklury	892		284		623		1,799		972		408		805		2,184		1,575		702		1,628		3,905
Oncology
Cell Therapy
Tecartus	234		138		31		403		245		110		15		370		221		75		3		299
Yescarta	662		666		242		1,570		811		547		140		1,498		747		355		57		1,160
Total Cell Therapy	896		804		274		1,973		1,055		658		156		1,869		968		430		60		1,459
Trodelvy	902		294		119		1,315		777		217		68		1,063		525		143		12		680
Total Oncology	1,798		1,098		393		3,289		1,833		875		224		2,932		1,494		573		73		2,139
Other
AmBisome	44		276		212		533		43		260		189		492		57		258		182		497
Other(5)	255		34		68		356		261		40		66		367		331		65		53		449
Total Other	299		310		280		889		304		301		255		859		388		323		235		946
Total product sales	20,508		4,576		3,526		28,610		19,377		4,197		3,361		26,934		18,716		4,342		3,924		26,982
Royalty, contract and other revenues	82		58		4		144		62		114		7		182		168		127		4		299
Total revenues	$	20,591	$	4,634	$	3,529	$	28,754	$	19,438	$	4,310	$	3,368	$	27,116	$	18,884	$	4,469	$	3,928	$	27,281

_______________________________

(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). See Note 7. Collaborations and Other Arrangements for additional information.

(2)    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.

(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi.

(5)    Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.

(6)    All individual international locations accounted for less than 10% of Total revenues.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:

	Year Ended December 31,
(as a percentage of total revenues)	2024		2023		2022
Cardinal Health, Inc.	26	%	26	%	25	%
Cencora, Inc.	18	%	19	%	18	%
McKesson Corporation	20	%	21	%	20	%

Revenues Recognized from Performance Obligations Satisfied in Prior Years

The following table summarizes revenues recognized from performance obligations satisfied in prior years:

	Year Ended December 31,
(in millions)	2024		2023		2022
Revenue share with Janssen(1) and royalties for licenses of intellectual property	$	727	$	680	$	783
Changes in estimates	$	452	$	340	$	582

_______________________________

(1)    See Note 7. Collaborations and Other Arrangements for additional information.

Contract Balances

The following table summarizes our contract balances:

	December 31,
(in millions)	2024		2023
Contract assets	$	277	$	117
Contract liabilities(1)	$	58	$	109

_______________________________

(1)    Future revenues recognized from contract liabilities are not expected to be material in any one year.